Quick Answer
Genenta Science S.p.A. reported Cash and Equivalents of $4.58 million for fiscal year 2024.
Genenta Science S.p.A. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $4.58M | +24.1% |
| 2023 | $3.69M | -87.6% |
| 2022 | $29.79M | -20.0% |
| 2021 | $37.24M | +140.8% |
| 2020 | $15.47M | — |
- Genenta Science S.p.A. showed an increase of +24.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2024 period, Genenta Science S.p.A.’s cash and equivalents has declined by 70.4% (from $15.47 million to $4.58 million).
- The most recent figure is from Genenta Science S.p.A.’s fiscal year 2024 report (Form 20-F), filed with the SEC on March 28, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: